Revolution Medicines, Inc. (NASDAQ:RVMD) CFO Jack Anders Sells 1,864 Shares

Revolution Medicines, Inc. (NASDAQ:RVMD) CFO Jack Anders sold 1,864 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $39.04, for a total transaction of $72,770.56. Following the completion of the transaction, the chief financial officer now owns 115,006 shares in the company, valued at $4,489,834.24. This represents a 1.59 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Revolution Medicines Stock Performance

Shares of RVMD opened at $38.75 on Thursday. The stock has a market capitalization of $7.20 billion, a P/E ratio of -10.79 and a beta of 1.46. Revolution Medicines, Inc. has a 1 year low of $29.55 and a 1 year high of $62.40. The company’s fifty day moving average is $40.74 and its two-hundred day moving average is $45.78.

Revolution Medicines (NASDAQ:RVMD) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.11). Sell-side analysts predict that Revolution Medicines, Inc. will post -3.49 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on RVMD. Stifel Nicolaus lowered their target price on shares of Revolution Medicines from $80.00 to $78.00 and set a “buy” rating for the company in a report on Thursday, February 27th. Needham & Company LLC dropped their price objective on Revolution Medicines from $60.00 to $59.00 and set a “buy” rating on the stock in a report on Thursday, February 27th. Guggenheim boosted their target price on Revolution Medicines from $82.00 to $87.00 and gave the company a “buy” rating in a report on Tuesday, December 3rd. UBS Group raised their price target on Revolution Medicines from $65.00 to $71.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. Finally, HC Wainwright boosted their price objective on Revolution Medicines from $72.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, March 3rd. Twelve research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $66.31.

Hedge Funds Weigh In On Revolution Medicines

A number of large investors have recently modified their holdings of the business. IFP Advisors Inc purchased a new stake in shares of Revolution Medicines in the fourth quarter valued at approximately $34,000. Quarry LP purchased a new stake in shares of Revolution Medicines during the 3rd quarter worth $82,000. Sterling Capital Management LLC grew its stake in shares of Revolution Medicines by 588.7% during the 4th quarter. Sterling Capital Management LLC now owns 1,956 shares of the company’s stock worth $86,000 after purchasing an additional 1,672 shares during the period. Farther Finance Advisors LLC increased its holdings in shares of Revolution Medicines by 368.3% in the 4th quarter. Farther Finance Advisors LLC now owns 2,051 shares of the company’s stock valued at $90,000 after purchasing an additional 1,613 shares in the last quarter. Finally, Kapitalo Investimentos Ltda acquired a new stake in shares of Revolution Medicines in the fourth quarter valued at about $104,000. 94.34% of the stock is owned by hedge funds and other institutional investors.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.